DDInter1143 DDInter899
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and intravenous formulations. It is a preferential COX-2 inhibitor, purportedly reducing the risk of adverse gastrointestinal tract effects, however, this is a topic of controversy.[A190198,A190201]
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Meloxicam {u} (Compound) resembles {v} (Compound) Piroxicam
Meloxicam {u} (Compound) binds {v} (Gene) CYP2C9
Meloxicam {u} (Compound) palliates {v} (Disease) systemic lupus erythematosus
Meloxicam {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Meloxicam {u} (Compound) causes {v} (Side Effect) Stevens-Johnson syndrome
Meloxicam {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linaclotide
Meloxicam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lumacaftor
Meloxicam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pegaspargase
Meloxicam {u} may lead to a major life threatening interaction when taken with {v} Warfarin
Meloxicam {u} may lead to a major life threatening interaction when taken with {v} Prasugrel
Meloxicam (Compound) resembles Piroxicam (Compound)
Meloxicam (Compound) binds CYP2C9 (Gene)
Meloxicam (Compound) palliates systemic lupus erythematosus (Disease)
Meloxicam (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class)
Meloxicam (Compound) causes Stevens-Johnson syndrome (Side Effect)
Meloxicam may cause a minor interaction that can limit clinical effects when taken with Linaclotide
Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase
Meloxicam may lead to a major life threatening interaction when taken with Warfarin
Meloxicam may lead to a major life threatening interaction when taken with Prasugrel